Our leadership team brings a powerful combination of proven clinical, strategic, and commercial capabilities to position the company for success.
Chief Executive Officer and President
Steven Katz, MD, FACS
Chief Medical Officer and Chairman SAB
Chief Financial Officer
Chief Commercial Officer
Bryan F. Cox, PhD
Chief of Research
Chief Regulatory Officer
Ms. Szela has nearly 30 years of experience in both the commercial and clinical arenas. Her accomplishments in building billion-dollar businesses, turning around faltering businesses, igniting growth in stagnant businesses, and devising innovative, differentiated strategies for undistinguished products make for a remarkable record.
Previously, Ms. Szela served as Chief Executive Officer of Novelion Therapeutics, a rare disease company, where she orchestrated the merger of Aegerion Pharmaceuticals and QLT Therapeutics. Prior to Novelion, she was Chief Executive Officer of Melinta Therapeutics, leading the company’s revitalization effort and accelerating clinical development of its lead asset for treatment of MRSA (methicillin-resistant Staphylococcus aureus).
Ms. Szela held ascending management positions at Abbott Laboratories including President of the company’s $8 billion U.S. pharmaceutical business. She developed global brands such as Humira® and served as Vice President for global strategic marketing and services. Ms. Szela currently serves as a member of the Board of Directors for Coherus Biosciences.
She earned an MBA and a BS in nursing, both from the University of Illinois.
Steven Katz, MD, FACS
Dr. Katz joined TriSalus in 2018 as Chief Medical Advisor and Chairman of the Scientific Advisory Board. In September 2020, Dr. Katz became Chief Medical Officer of TriSalus. Previously, he was Director of the Office of Therapeutic Development at Roger Williams Medical Center. He also serves as Associate Professor of Surgery at Boston University School of Medicine. Dr. Katz attended the New York University School of Medicine, receiving the Alpha Omega Alpha Award. He completed his general surgery residency at the New York University Medical Center and fellowships in Immunology and Surgical Oncology at the Memorial Sloan-Kettering Cancer Center, where he served as the Chief Administrative Fellow. His clinical expertise is in liver surgery, pancreatic surgery, sarcoma, and melanoma.
His laboratory research endeavors focus on immunotherapy for liver metastases and sarcoma. He has invented numerous cell therapy products and methods currently under testing or development. Dr. Katz has received research grants from numerous societies and the NIH and DOD. He has led five solid tumor CAR-T clinical trials, testing novel delivery approaches. Dr. Katz serves as a reviewer for several scientific and clinical journals and is a member of the Cancer Gene Therapy editorial board, among others. Dr. Katz also participates on NIH study sections and American Board of Surgery exam committees.
Scott Davie has more than 25 years of medical device experience, creating and leading teams to deliver innovative, complex, high quality systems from conceptualization to market launch and end of life cycle. He spent the majority of his career at Medtronic. He possesses a deep understanding of clinical workflow and use cases across a variety of medical specialties. Throughout his career, he has developed implantable defibrillators, pacemakers, and pressure sensors; ablation catheters and consoles. His regulatory experience includes 510k’s, PMA-S, original PMAs, and CE Marks, and he has global experience having lived in Spain, Japan, and Canada.
Scott earned his Bachelor of Science in Mechanical Engineering from MIT and his Master of Science in Mechanical Engineering from Stanford with a focus on Biomechanics and Electronics.
Raj joined TriSalus in June 2020 and serves as Chief Financial Officer. With nearly 15 years of experience within the healthcare industry, Raj has broad management expertise extending from VC-backed start-ups to publicly-traded, multinational corporations where he drove corporate development and strategy, corporate finance, and investment banking efforts. Prior to his work with TriSalus, Raj was head of Corporate Development at Option Care Health, a healthcare services company focused on alternate site infusion therapy.
Raj also served as Director of Strategic Finance & Investor Relations at Melinta Therapeutics, Inc., a biotech focused on the discovery, development and commercialization of novel antibiotics. In addition, Raj held various financial and corporate M&A roles of increasing responsibility at Baxter International, a global medical device manufacturer, and began his career in healthcare investment banking at A.G. Edwards Capital Markets (now owned by Wells Fargo.)
Raj earned his Bachelor of Science in Finance from Indiana University’s Kelley School of Business.
Bryan F. Cox, PhD
Dr. Bryan Cox joins TriSalus as Chief of Research with an emphasis on pharmaceuticals. Dr. Cox has extensive experience working with due diligence teams as they determine the best path forward from early discovery to first-in-man studies, including involvement in projects resulting in U.S. FDA regulatory approval such as Baxalta®, Gocovri®, Giapreza®, Tricor®, and Orilissa®. He has (co-) authored/approved over 250 documents for Regulatory submission and participated in the advancement of over 60 compounds to Phase I clinical trials.
Prior to TriSalus, Dr. Cox was President of CoPharm Global Consulting and spent 17 years at Abbott/Abbvie as Director of Integrative Pharmacology, responsible for both lead optimization and IND-enabling studies. In addition, Dr. Cox was a charter member of the technical assessment team for Abbott BioVentures and spent over 20 years serving on their due diligence teams. Prior to joining Abbott, Dr. Cox was with Rhone Poulenc Rorer. Dr. Cox has published more than 100 papers in peer reviewed journals and has twice been elected to the Council for the American Society of Pharmacology and Experimental Therapeutics.
He received his PhD in Pharmacology from the University of Iowa and is currently an adjunct Professor of Pharmacology at the University of Iowa, College of Medicine.
Trevor joined TriSalus in October 2020 and serves as Chief Commercial Officer. With extensive experience as a commercial leader in the healthcare industry, Trevor is instrumental in the Company’s integration of novel therapies with innovative drug delivery. Trevor is working to improve patient lives especially for those with the most intractable forms of cancer, namely solid tumors of the liver and the pancreas.
Prior to joining TriSalus, Trevor served as President and Chief Commercial Officer of Clerio Vision and President and Chief Operating Officer for Blueprint Clinical, where he oversaw the development and commercialization of COMPASS, a leading risk-based monitoring analytic platform for clinical trials. In addition, Trevor founded Aegis Medical Innovations of Vancouver, and oversaw the fundraising, operations, R&D and clinical trials, specifically the break-through implantable cardiovascular stroke prevention device licensed from the Mayo Clinic.
Trevor received his Bachelor of Applied Science in Electrical Computer Engineering from Queen’s University, Kingston, Canada, and a Master of in Business from Harvard School of Business, Cambridge, MA.
Jennifer joined TriSalus in March 2021 as Senior Vice President, Pharmaceutical Regulatory Affairs. She brings us expertise in regulatory affairs, law, and policy developed over nearly 30 years of advising clients as a regulatory leader in industry, a regulator at the FDA, and an attorney/partner in several law firms, including Kirkland & Ellis, Willkie, Farr & Gallagher, and Pillsbury, where her work included counseling regulated industry.
Most recently, Jennifer was Executive Director, Immuno-Oncology/Oncology, Global Regulatory Affairs at EMD Serono (Merck KGaA) where she had oversight responsibility for early and late-stage immuno-oncology/oncology assets. Her accomplishments included regulatory approvals globally for Bavencio, an anti-PD1 therapy being developed in collaboration with Merck KGaA/Pfizer, including BLAs/sBLAs (Merkel Cell carcinoma, 2L urothelial carcinoma (UC), Renal Cell carcinoma, and 1L UC maintenance). Her work also included due diligence projects for in-licensing/purchase of early/mid-stage assets.
Before EMD, Jennifer spent 4+ years as Counsel at the FDA, advising on regulations, policy, and agency guidance.
Jennifer received her bachelor’s degree from the University of Illinois and her JD from George Washington University, graduating cum laude from both institutions.